DG-031 (formerly Bay x 1005)
Jump to navigation
Jump to search
Indications
(investigational uses)
- treatment of asthma
- reduction of risk factors for myocardial infarction
Dosage
Mechanism of action
- binds to & inhibits 5-lipoxygenase activating protein (FLAP)
- prevents translocation of 5-lipoxygenase from the cytosol to membrane* also bound by 5 lipoxygenase
- DG-013 reduces leukotriene B4 26%, myeloperoxidase 12% & C-reactive protein# 16%[1]
* perinuclear membrane? (see FLAP)
# not statistically significant[1]
More general terms
Additional terms
References
- ↑ 1.0 1.1 1.2 Hakonarson H, Thorvaldsson S, Helgadottir A, Gudbjartsson D, Zink F, Andresdottir M, Manolescu A, Arnar DO, Andersen K, Sigurdsson A, Thorgeirsson G, Jonsson A, Agnarsson U, Bjornsdottir H, Gottskalksson G, Einarsson A, Gudmundsdottir H, Adalsteinsdottir AE, Gudmundsson K, Kristjansson K, Hardarson T, Kristinsson A, Topol EJ, Gulcher J, Kong A, Gurney M, Thorgeirsson G, Stefansson K. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA. 2005 May 11;293(18):2245-56. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15886380